Review article: Putting immediate-release proton-pump inhibitors into clinical practice - Improving nocturnal acid control and avoiding the possible complications of excessive acid exposure

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 3, 2005, Pages 31-38

  Katz, P O ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ACIDITY; BARRETT ESOPHAGUS; CLINICAL PRACTICE; DELAYED RELEASE FORMULATION; DRUG EFFICACY; DRUG FORMULATION; ESOPHAGEAL ADENOCARCINOMA; EXPOSURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; IMMEDIATE RELEASE FORMULATION; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; RISK FACTOR; SLEEP DISORDER; STOMACH ACID; SYMPTOMATOLOGY;

EID: 28944454416     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02712.x     Document Type: Review

References (37)

1. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52.
2. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98: 1487-93.
3. McColl E, Junghard O, Wiklund I, Revicki DA. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005; 100: 11-8.
4. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
5. Katzka DA, Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989-91.
6. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6.
7. Ouatu-Lascar R, Fitzgerald RC. Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35.
8. El-Serag H, Aguirre T, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83.
9. Banerjee P, Ahmad F, Tutuian R, et al. Is normal esophageal acid exposure on pH monitoring in Barrett's patients maintained on repeated testing? Gastroenterology 2003; 124: A539 (Abstract).
10. Spechler S, Sharma P, Traxler B, Levine D, Falk G. Effect of esomeprazole on intraesophageal pH in patients with Barrett's esophagus. Am J Gastroenterol 2004; 99: S16 (Abstract).
11. Maqbool S, Bhat Y, Khandwala F, Vaezi M. Barrett's esophagus: how much acid suppression is enough? Predictors of response to high dose proton pump inhibitors. Am J Gastroenterol 2004; 99: S10 (Abstract).
12. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
13. Katz P, Sachs G. Mechanism of action and safety of heartburn therapies. Pract Gastroenterol 2003; 27: 80-8.
14. Tutuian R, Castell DO. Nocturnal acid breakthrough - approach to management. MedGenMed 2004; 6: 11.
15. Tutuian R, Katz P, Castell D. A PPI is a PPI is a PPI: lessons from prolonged intragastric pH monitoring. Gastroenterology 2000; 118: A17 (Abstract).
16. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
17. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO Study. Aliment Pharmacol Ther 2005; 21: 739-46.
18. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998; 93: 763-7.
19. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-4.
20. Fouad YM, Katz PO, Castell DO. Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999; 13: 1467-71.
21. Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 22: 129-34.
22. Hammer J, Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004; 19: 1105-10.
23. Hatlebakk JG, Katz PO, Castell DO. Medical therapy. Management of the refractory patient. Gastroenterol Clin North Am 1999; 28: 847-60.
24. Fass R, Sampliner RE, Malagon IB, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000; 14: 597-602.
25. Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527-31.
26. Sobrino-Faya M, Vilarino-Insua M, Iglesias-Canle J, Martinez S, Dominguez-Munoz J. Is it worthwhile to delay the bedtime after dinner in patients with gastroesophageal reflux disease (GERD)? Gastroenterology 2005; 128: A384 (Abstract M1747).
27. Khoury RM, Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 2069-73.
28. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267-72.
29. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 1532-8.
30. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40.
31. Pehlivanov ND, Olyaee M, Sarosiek I, McCallum RW. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003; 18: 883-90.
32. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115: 1335-9.
33. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 625-32.
34. Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6.
35. Khoury RM, Katz PO, Hammod R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13: 675-8.
36. Package insert: Immediate-release omeprazole [(IR-OME) Zegerid® power for oral suspension; Santarus, Inc., San Diego, CA, USA]. December 2004.
37. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005; 21: 1467-74.